Platinum Chemotherapy Hypersensitivity : Prevalence and Management - 30/09/17

Doi : 10.1016/j.iac.2017.06.003

Iris M. Otani, MD ^a,^⁎ , Johnson Wong, MD ^b, Aleena Banerji, MD ^b
^a Department of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, UCSF Medical Center, 400 Parnassus Avenue, Fifth Floor, San Francisco, CA 94143, USA
^b Department of Medicine, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA

^∗Corresponding author.

Résumé

Hypersensitivity reactions to platinum agents are common. For carboplatin and cisplatin, the first hypersensitivity reaction typically occurs around the second and third re-exposure during the second line of therapy (eighth and ninth courses overall). For oxaliplatin, the first hypersensitivity reaction can occur throughout the treatment course. Skin testing helps risk stratify patients to appropriate desensitization protocols and assess risk for breakthrough HSRs during desensitization. A risk-stratification protocol using 3 serial skin tests and desensitization protocols enables patients with platinum agent hypersensitivity to receive first-line chemotherapy treatment safely.

Le texte complet de cet article est disponible en PDF.

Keywords : Platinum agent, Carboplatin, Cisplatin, Oxaliplatin, Chemotherapy allergy, Chemotherapy hypersensitivity, Chemotherapy desensitization